Lumos Diagnostics Holdings Limited

Reported revenue for Q3 FY26 was $4.8 million ($4.822 million), up 37% versus Q3 FY25. Product revenue was $2.4 million versus $0.7 million a year ago, while services revenue was $2.4 million versus $2.8 million, with the prior period helped by $0.8 million of IP revenue. Year-to-date revenue was $10.9 million, up 11% year on year. Net cash outflow for the quarter was $3.1 million, compared with $1.6 million in the prior corresponding period, and cash at March 31 was $1.1 million. Management said FebriDx can start at about 60% gross margin and could rise to about 80% over the PHASE agreement period. On the PHASE contract, Lumos said $8.5 million has been paid to date, with another $308 million committed over years 2 through 6. After quarter-end, the company said it received $20 million of placement proceeds before costs, a $5 million PHASE prepayment, and invoiced BARDA for a $0.5 million final milestone payment. Guidance was qualitative rather than numeric: management expects revenue uplift from PHASE and FebriDx commercialization, but did not provide formal forward revenue guidance.

Douglas Ward framed the quarter as a turning point because the company now has CLIA waiver status and can move FebriDx from the more limited moderate-complexity setting into urgent care and primary care. He emphasized that the test addresses an unmet need by helping clinicians distinguish bacterial from viral respiratory infections and therefore improve antibiotic decisions. His tone was upbeat and execution-focused, with repeated references to the U.S. rollout, distributor activation, and building a playbook from early pilots like WellStreet.

Barrie Lambert focused on the quarter’s financial bridge: $4.8 million in revenue, $2.4 million from products, $2.4 million from services, and a $3.1 million net cash outflow. He also highlighted that the company drew down a $1 million line facility during the quarter, then received $20 million of placement proceeds and a $5 million PHASE prepayment after quarter-end, with another $0.5 million BARDA milestone expected soon. On margins and unit economics, he said FebriDx should begin at roughly 60% gross margin and could improve to around 80% as volumes and supplier contracts scale.

Analysts asked about Australian Medicare reimbursement, and management said it is still being pursued through additional local data and a comparative study with the University of Wollongong after the initial approach did not succeed. Questions also focused on whether the U.S. antibiotic-stewardship plan could help FebriDx; management said it is supportive but will take time to translate into commercial impact. On PHASE, Barrie clarified that the initial $2.5 million prepayment has been fully shipped and recognized, while the later $5 million prepayment has not yet shipped and will be recognized as product is manufactured. Management also said the pediatric study is ongoing and likely runs into the end of the calendar year, and that broader sales/revenue updates will likely wait for the next quarterly report unless something material occurs sooner.